Cinacalcet versus Parathyroidectomy in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation

1. PERRIN P., CAILLARD S., JAVIER RM., et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. American Journal of Transplantation. 2013; 13(10): 2653-2663.10.1111/ajt.1242524034142Search in Google Scholar

2. MAZZAFERRO S., PASQUALI M., TAGGI F., et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clinical Journal of the American Society of Nephrology. 2009; 4(3): 685-690.10.2215/CJN.03930808265365719211668Search in Google Scholar

3. GWINNER W., SUPPA S., MENGEL M., et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. American Journal of Transplantation. 2005; 5(8): 1934-1941.10.1111/j.1600-6143.2005.00938.x15996242Search in Google Scholar

4. Cohen JB., Gordon CE., Balk EM., Francis JM., et al. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: A systematic review and meta-analysis. Transplantation. 2012; 94(10): 1041-1048.10.1097/TP.0b013e31826c396823069843Search in Google Scholar

5. PASCHOALIN RP., TORREGROSA JV., SÁNCHEZ-ESCUREDO A., BARROS X., DURÁN CE., CAMPISTOL JM., et al Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up. Transplantation Proceedings. 2012; 44(9): 2588-2589.10.1016/j.transproceed.2012.09.04923146463Search in Google Scholar

6. LINDBERG J.S., CULLETON B., WONG G., et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology. 2005; 16(3): 800-807.10.1681/ASN.200406051215689407Search in Google Scholar

7. PALMER S.C., NISTOR I., CRAIG J.C., et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Medicine. 2013; 10(4).10.1371/journal.pmed.1001436364008423637579Search in Google Scholar

8. PASCHOALIN R.P., TORREGROSA J.V., BARROS X., DURAN C.E., CAMPISTOL J.M. et al. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal. Transplantation proceedings. 2012; 44(8): 2376-2378.10.1016/j.transproceed.2012.07.04923026597Search in Google Scholar

9. TORREGROSA J.V., MORALES E., DIAZ J.M., et al. Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study. Nephrology. 2014; 19(2): 84-93.10.1111/nep.1218624428216Search in Google Scholar

10. MESSA P., CAFFORIO C., ALFIERI C., et al. Clinical impact of hypercalcemia in kidney transplant. International Journal of Nephrology. 2011; 2011:9.10.4061/2011/906832313280221760999Search in Google Scholar

11. MUIRHEAD N., ZALTMAN J.S., GILL J.S., et al. Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice. Clinical Transplantation. 2014; 28(2): 161-165.10.1111/ctr.1229124329899Search in Google Scholar

12. TORREGROSA J.V., BARROS X. Management of hypercalcemia after renal transplantation. Nefrologia. 2013; 33(6): 751-757.Search in Google Scholar

13. EVENEPOEL P., CLAES K., KUYPERS D.R., DEBRUYNE F., VANRENTERGHEM Y., et al. Parathyroidectomy after successful kidney transplantation: a single center study. Nephrology Dialysis Transplantation. 2007; 22(6): 1730-1737.10.1093/ndt/gfm04417371780Search in Google Scholar

14. ROJAS E., CARLINI R.G., CLESCA P., et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney International. 2003; 63(5): 1915-1923.10.1046/j.1523-1755.2003.00938.x12675872Search in Google Scholar

15. NAGANO N., NEMETH E.F. Functional proteins involved in regulation of intracellular Ca2+ for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetic. Journal of Pharmacological Sciences. 2005; 97(3): 355-360.10.1254/jphs.FMJ04007X615781990Search in Google Scholar

16. LINDBERG J.S., CULLETON B., WONG G., et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology. 2005; 16(3): 800-807.10.1681/ASN.200406051215689407Search in Google Scholar

17. GUERRA R., SAAVEDRA I.A., FERNANDEZ E.J., et al. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with Cinacalcet. Journal of Nephrology. 2011; 24(1): 78-82. 10.5301/JN.2010.293Search in Google Scholar